Company Precigen, Inc.

Equities

PGEN

US74017N1054

Pharmaceuticals

Market Closed - Nasdaq 03:59:54 2024-03-28 pm EDT 5-day change 1st Jan Change
1.44 USD -0.69% Intraday chart for Precigen, Inc. -5.88% +7.46%

Business Summary

Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Number of employees: 202

Sales per Business

USD in Million2022Weight2023Weight Delta
Exemplar
98.8 %
12 44.7 % 6 98.8 % -48.81%
Biopharmaceuticals
1.2 %
15 55.3 % 0 1.2 % -99.50%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
27 99.1 % 6 100.0 % -76.66%

Managers

Managers TitleAgeSince
Chief Executive Officer 62 19-12-31
Director of Finance/CFO 62 21-09-30
Chairman 70 08-01-31
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Investor Relations Contact - 17-12-31
Corporate Officer/Principal - -
Human Resources Officer - -
General Counsel 49 08-12-31
Corporate Officer/Principal 59 -

Members of the board

Members of the board TitleAgeSince
Chairman 70 08-01-31
Director/Board Member 68 09-02-28
Corporate Officer/Principal 52 14-07-31
Director/Board Member 78 16-06-29
Director/Board Member 68 11-11-27
Director/Board Member 76 08-01-31
Director/Board Member 69 14-04-15
Director/Board Member 64 08-01-31
Director/Board Member 56 17-04-24
Chief Executive Officer 62 19-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 256,398,527 220,754,404 ( 86.10 %) 7,479,431 ( 2.917 %) 86.10 %

Shareholders

NameEquities%Valuation
Third Security LLC
38.98 %
97,040,956 38.98 % 149 M $
MERCK KGAA
8.295 %
20,647,152 8.295 % 32 M $
Patient Capital Management LLC
6.421 %
15,983,700 6.421 % 25 M $
Patient Capital Management LLC (Invt Mgmt)
6.421 %
15,983,700 6.421 % 25 M $
Patient Capital Management, Inc.
5.223 %
13,000,000 5.223 % 20 M $
BlackRock Advisors LLC
4.253 %
10,587,382 4.253 % 16 M $
Vanguard Fiduciary Trust Co.
2.711 %
6,748,359 2.711 % 10 M $
Geode Capital Management LLC
1.214 %
3,021,297 1.214 % 5 M $
Millennium Management LLC
1.143 %
2,845,911 1.143 % 4 M $
2,684,533 1.078 % 4 M $

Company contact information

Precigen, Inc.

20374 Seneca Meadows Parkway

20876, Germantown

+301 556 9900

http://www.precigen.com
address Precigen, Inc.(PGEN)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.45 USD
Average target price
9 USD
Spread / Average Target
+520.69%
Consensus